查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1621892

蛋白酶 K 市场机会、成长动力、产业趋势分析及 2024 年至 2032 年预测

Proteinase K Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 to 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年，全球蛋白酶 K 市场规模约为 13 亿美元，预计 2024 年至 2032 年复合年增长率为 7.5%。慢性病和传染病是主要驱动因素，因为蛋白酶 K 在与这些疾病相关的分子诊断和研究中发挥关键作用。导致慢性疾病增加的因素包括人口老化、久坐的生活方式和不良的饮食习惯，进而导致心血管疾病、糖尿病和癌症等疾病。同时，城市化、全球旅行和抗菌素抗药性的增加推动了传染病的传播。

从形式来看，粉末细分市场占据主导地位，2023 年销售额达 7.357 亿美元。这种稳定性对于实验室应用至关重要，因为酵素必须在不冷藏的情况下长时间保持活性。此外，粉末製剂通常具有较低的生产和运输成本，这使得它们对实验室来说更加经济，尤其是涉及大规模应用的实验室。根据治疗领域，蛋白酶K市场分为传染病、肿瘤学、糖尿病、心臟病学和其他治疗领域。

预计到 2032 年，传染病领域将达到 7.953 亿美元。蛋白酶 K 在从病原体中分离和纯化核酸方面发挥着重要作用，这对于分子诊断至关重要。这大大增加了对利用蛋白酶KUS 的诊断工具的需求，在北美蛋白酶K 市场占据主导地位，2023 年收入最高为4.562 亿美元。的高消费量。此外，传染病带来的持续挑战提高了对利用蛋白酶 K 进行快速测试和研究能力的需求，从而推动了对核酸提取中涉及的酶的需求。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 13亿美元
预测值 25亿美元
复合年增长率 7.5%

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 慢性病和传染病的盛行率不断上升
      • 生物技术的进步
      • 技术进步
      • 政府对研究的投资
    • 产业陷阱与挑战
      • 酵素的成本高
  • 成长潜力分析
  • 监管环境
  • 技术景观
  • 未来市场趋势
  • 差距分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按形式，2021 - 2032

  • 主要趋势
  • 粉末
  • 液体

第 6 章：市场估计与预测：按治疗领域，2021 - 2032 年

  • 主要趋势
  • 传染病
  • 肿瘤学
  • 糖尿病
  • 心臟病学
  • 其他治疗领域

第 7 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 基因组 DNA 和 RNA 的分离与纯化
  • 原位杂交
  • 粒线体分离
  • 其他应用

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 生技公司
  • 合约研究组织
  • 诊断实验室
  • 其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 10 章：公司简介

  • Abcam
  • Agilent Technologies
  • Bioline (Meridian Biosciences)
  • BIORON
  • F. Hoffmann-La Roche
  • Merck
  • Minerva Biolabs
  • MP BIOMEDICALS.
  • New England Biolabs
  • Norgen Biotek
  • Promega Corporation
  • QIAGEN
  • Sisco Research Laboratories
  • Takara Bio
  • Thermo Fisher Scientific
简介目录
Product Code: 11996

The Global Proteinase K Market size was worth around USD 1.3 billion in 2023 and is estimated to grow at 7.5% CAGR from 2024 to 2032. The increasing prevalence of chronic and infectious diseases, along with advancements in biotechnology, is driving market growth. Chronic and infectious diseases are major drivers, as proteinase K plays a critical role in molecular diagnostics and research related to these conditions. Contributing factors to the rise in chronic diseases include an aging population, sedentary lifestyles, and poor dietary habits, leading to conditions such as cardiovascular diseases, diabetes, and cancer. Meanwhile, the spread of infectious diseases is driven by urbanization, global travel, and the rise of antimicrobial resistance.

Based on form, the powder segment dominated the market and accounted for USD 735.7 million in 2023. Powdered proteinase K is more stable than its liquid counterpart, offering a longer shelf life and easier storage conditions. This stability is essential for laboratory applications where enzymes must retain activity over extended periods without refrigeration. Additionally, powdered formulations typically have lower production and shipping costs, making them more economical for laboratories, especially those involved in large-scale applications. Based on therapeutic areas, the proteinase K market is segmented into infectious diseases, oncology, diabetes, cardiology, and other therapeutic areas.

The infectious diseases segment is anticipated to reach USD 795.3 million by 2032. The increasing prevalence of infectious diseases worldwide drives the demand for rapid and accurate diagnostic tests. Proteinase K plays an essential role in the isolation and purification of nucleic acids from pathogens, which is crucial for molecular diagnostics. This significantly bolsters the demand for diagnostic tools that utilize proteinase K. U.S. dominated the North American proteinase K market with the largest revenue of USD 456.2 million in 2023. The U.S. hosts numerous academic and research institutions engaged in genetic and cellular research, leading to high consumption of proteinase K.This indicates that the growth in federal funding for scientific research supports a continuous need for molecular biology tools, including enzymes. Additionally, the ongoing challenges posed by infectious diseases have heightened the need for rapid testing and research capabilities that utilize proteinase K, thereby driving the demand for enzymes involved in nucleic acid extraction.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$1.3 Billion
Forecast Value$2.5 Billion
CAGR7.5%

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of chronic and infectious diseases
      • 3.2.1.2 Advancements in biotechnology
      • 3.2.1.3 Technological progress
      • 3.2.1.4 Government investment in research
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of enzymes
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Future market trends
  • 3.7 Gap analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Form, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Powder
  • 5.3 Liquid

Chapter 6 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Infectious diseases
  • 6.3 Oncology
  • 6.4 Diabetes
  • 6.5 Cardiology
  • 6.6 Other therapeutic areas

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Isolation and purification of genomic DNA & RNA
  • 7.3 In situ hybridization
  • 7.4 Mitochondria isolation
  • 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Biotechnology companies
  • 8.3 Contract research organizations
  • 8.4 Diagnostic laboratories
  • 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Abcam
  • 10.2 Agilent Technologies
  • 10.3 Bioline (Meridian Biosciences)
  • 10.4 BIORON
  • 10.5 F. Hoffmann-La Roche
  • 10.6 Merck
  • 10.7 Minerva Biolabs
  • 10.8 MP BIOMEDICALS.
  • 10.9 New England Biolabs
  • 10.10 Norgen Biotek
  • 10.11 Promega Corporation
  • 10.12 QIAGEN
  • 10.13 Sisco Research Laboratories
  • 10.14 Takara Bio
  • 10.15 Thermo Fisher Scientific